
|Articles|June 14, 2007
Wavelight riding high on new Eye-Q approval
The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.
Advertisement
The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.
The Eye-Q wavefront-guided LASIK procedure has been approved for the reduction or elimination of up to -7.00 D of spherical equivalent (SE) of myopia or myopia with astigmatism, with up to -7.00 D of spherical component and up to 3.00 D of astigmatic component at the spectacle plane.
The Eye-Q system has also been approved by the US regulatory body for the reduction or elimination of naturally occurring mixed astigmatism of up to 6.00 D at the spectacle plane
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











